Difamilast ointment, a selective phosphodiesterase 4 inhibitor, in paediatric patients with atopic dermatitis: A phase 3 randomised double‐blind, vehicle‐controlled trial

SAT0392 Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of A Phase 3, Randomized, Controlled Trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2014-eular.4419 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 736.1-736 ◽

Cited By ~ 1

Author(s):

F. Zhang ◽

T. Tencer ◽

S. Li

Keyword(s):

Randomized Controlled Trial ◽

Psoriatic Arthritis ◽

Controlled Trial ◽

Work Productivity ◽

Phase 3 ◽

Productivity Improvement ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

A Novel Nonsteroidal, Topical Anti-inflammatory, Phosphodiesterase 4 Inhibitor, Crisaborole Ointment, Reduced Pruritus and Signs of Atopic Dermatitis in 2 Phase 3 Studies in Children and Adults

10.1542/peds.141.1_meetingabstract.251 ◽

2018 ◽

Author(s):

Adelaide A. Hebert ◽

Lawrence F. Eichenfield ◽

Mark G. Lebwohl ◽

Amy S. Paller ◽

Eric L. Simpson ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Anti Inflammatory ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

LB0001 Long-Term (52-Week) Results of a Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.526 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A163-A163 ◽

Cited By ~ 5

Author(s):

A. Kavanaugh ◽

P. J. Mease ◽

A. O. Adebajo ◽

J. Wollenhaupt ◽

C. Hu ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

SAT0402 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pharmacodynamic Results of A Phase 3, Randomized, Controlled Trial (PALACE 1)

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2014-eular.3878 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 739.4-740 ◽

Cited By ~ 1

Author(s):

P. Schafer ◽

P. Chen ◽

L. Fang ◽

A. Wang ◽

R. Chopra

Keyword(s):

Randomized Controlled Trial ◽

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

SAT0377 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2014-eular.1575 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 730.2-730 ◽

Cited By ~ 1

Author(s):

A. Adebajo ◽

A. Wells ◽

C. Edwards ◽

A. Kivitz ◽

P. Bird ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Phase 3 Studies Treating Children and Adult Patients with Mild to Moderate Atopic Dermatitis with Crisaborole Ointment, a Novel, Nonsteroidal, Topical Anti-inflammatory, Phosphodiesterase 4 Inhibitor

10.1542/peds.141.1_meetingabstract.275 ◽

2018 ◽

Author(s):

Amy S. Paller ◽

Wynnis L. Tom ◽

Mark G. Lebwohl ◽

Mark Boguniewicz ◽

Lawrence F. Eichenfield ◽

...

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Anti Inflammatory ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2014.01.682 ◽

2014 ◽

Vol 70 (5) ◽

pp. AB164 ◽

Cited By ~ 1

Keyword(s):

Randomized Controlled Trial ◽

Controlled Trial ◽

Severe Psoriasis ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Crisaborole topical ointment, 2%: A novel, nonsteroidal, topical antiinflammatory, phosphodiesterase 4 inhibitor: Results from two phase 3 studies treating children and adult patients with mild to moderate atopic dermatitis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.02.337 ◽

2016 ◽

Vol 74 (5) ◽

pp. AB86 ◽

Cited By ~ 1

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Phase 3 ◽

Two Phase ◽

Phosphodiesterase 4 ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

214. Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Physical Function and Pain in Patients with Psoriatic Arthritis and Current Skin Involvement: Results of Palace 3, a Phase 3, Randomized, Controlled Trial

Rheumatology ◽

10.1093/rheumatology/keu115.008 ◽

2014 ◽

Vol 53 (suppl_1) ◽

pp. i139-i140 ◽

Cited By ~ 2

Author(s):

Christopher J. Edwards ◽

Francisco J. Blanco ◽

Jeffrey Crowley ◽

ChiaChi Hu ◽

Randall M. Stevens ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Psoriatic Arthritis ◽

Physical Function ◽

Controlled Trial ◽

Skin Involvement ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

OP0104 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.309 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A85.3-A86 ◽

Cited By ~ 4

Author(s):

C. Birbara ◽

F. J. Blanco ◽

J. J. Crowley ◽

C. Hu ◽

R. Stevens ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Psoriatic Arthritis ◽

Controlled Trial ◽

Skin Involvement ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text